22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
2
Interactions of hepatitis B core antigen and peptide inhibitors.
Universiti Putra Malaysia
3
Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators.
Shandong Second Medical University
2
Identification of peptide-based hepatitis B virus capsid inhibitors based on the viral core protein.
Shizuoka University
57
Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection.
Ocean University of China
4
Design, Synthesis, and Biological Evaluation of Novel Thioureidobenzamide (TBA) Derivatives as HBV Capsid Assembly Modulators.
Weifang Medical University
19
Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators.
Promidis
25
Discovery of SHR5133, a Highly Potent and Novel HBV Capsid Assembly Modulator.
Shanghai Hengrui Pharmaceutical
13
Identification of (6S)-cyclopropyl-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxamines as new HBV capsid assembly modulators.
Cams Key Laboratory of Antiviral Drug Research
15
Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.
Shandong University
21
SAR studies in the sulfonyl carboxamide class of HBV capsid assembly modulators.
Novira Therapeutics
21
A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles.
TBA
7
Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors.
Xuzhou Medical University
1
Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
Tsinghua University
8
Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.
Emory University
52
Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
Sunshine Lake Pharma
4
Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
Newave Pharmaceutical
30
Matrix metalloproteinase (MMP) inhibitors and methods of use thereof
Foresee Pharmaceuticals
22
N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
University of Michigan